iTeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest Down 21.1% in January

iTeos Therapeutics, Inc. (NASDAQ:ITOS) saw a large decrease in short interest during the month of January. As of January 15th, there was short interest totalling 1,500,000 shares, a decrease of 21.1% from the December 31st total of 1,900,000 shares. Based on an average trading volume of 556,500 shares, the days-to-cover ratio is presently 2.7 days. Currently, 4.9% of the company’s shares are short sold.

Insider Activity

In related news, CFO Matthew Gall acquired 5,000 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was bought at an average price of $7.73 per share, with a total value of $38,650.00. Following the purchase, the chief financial officer now directly owns 65,429 shares in the company, valued at $505,766.17. The trade was a 8.27 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 12.50% of the company’s stock.

Institutional Trading of iTeos Therapeutics

Large investors have recently bought and sold shares of the company. State Street Corp boosted its stake in shares of iTeos Therapeutics by 21.9% during the 3rd quarter. State Street Corp now owns 1,175,353 shares of the company’s stock valued at $12,000,000 after buying an additional 211,452 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of iTeos Therapeutics by 14.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock valued at $13,481,000 after buying an additional 117,159 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of iTeos Therapeutics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 640,350 shares of the company’s stock valued at $6,540,000 after buying an additional 20,092 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of iTeos Therapeutics by 1.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 467,319 shares of the company’s stock valued at $4,771,000 after buying an additional 5,368 shares during the last quarter. Finally, Algert Global LLC boosted its stake in shares of iTeos Therapeutics by 92.0% during the 3rd quarter. Algert Global LLC now owns 256,139 shares of the company’s stock valued at $2,615,000 after buying an additional 122,730 shares during the last quarter. Institutional investors and hedge funds own 97.16% of the company’s stock.

iTeos Therapeutics Trading Up 2.5 %

NASDAQ:ITOS traded up $0.19 during trading hours on Thursday, hitting $7.68. The stock had a trading volume of 227,461 shares, compared to its average volume of 292,098. iTeos Therapeutics has a 1-year low of $7.09 and a 1-year high of $18.75. The business has a 50 day simple moving average of $7.87 and a two-hundred day simple moving average of $11.10. The company has a market cap of $280.55 million, a PE ratio of -2.44 and a beta of 1.39.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.18) by $0.13. Research analysts expect that iTeos Therapeutics will post -3.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on ITOS shares. Wedbush reissued an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a research report on Friday, January 10th. HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of iTeos Therapeutics in a research report on Thursday, January 16th. Finally, Wells Fargo & Company dropped their target price on shares of iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.